|
Active substance
|
trastuzumab deruxtecan |
|
Holder |
Daiichi Sankyo Belgium N.V.-S.A |
|
Status |
Closed |
|
Indication |
adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens |
|
Public documents |
|
| Approbation amendment 1 | |
| Approbation amendment 2 | |
| Information for the patient - amendment 1 | |
| Information for the patient - amendment 2 | |
| Informed consent | |
| Informed consent - amendment 2 | |
|
Last update |
22/06/2023 |
Enhertu®
Last updated on 10/09/2024